肺鳞癌的免疫治疗进展

Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer

近几年来,肺鳞癌在化疗及靶向治疗上的进展不够显著,但免疫治疗却在肺鳞癌的治疗上取得了突破性的进展。免疫治疗通过免疫系统来清除肿瘤细胞,主要分为免疫检查点抑制剂及治疗性疫苗。免疫检查点抑制剂,包括抗细胞毒性T淋巴细胞抗原4(cytotoxic T-lymphocyte associated antigen 4,CTLA-4)抗体与抗程序性死亡受体-1(programmed death receptor 1,PD-1)抗体等多种药物已进行了肺鳞癌的Ⅱ期、Ⅲ期临床试验,并取得了一定成果。免疫治疗将成为肺鳞癌治疗的一种重要手段。

In recent years, squamous non-small cell lung cancer（NSCLC） didn＇t progress much in chemotherapy or target therapy. However, immunotherapy has made breakthroughs in treating squamous NSCLC. Immunotherapy includes two main broad classes of immune checkpoint inhibitors and therapeutic vaccines. Immune checkpoint inhibitors, including anti cytotoxic T-lymphocyte associated antigen 4（CTLA-4） and anti programmed death receptor 1（PD-1） antibodies, have been tested in the phase II/III clinical trials and have demonstrated promising outcomes. Immunotherapy will become an important treatment for squamous NSCLC.